HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Keith B. Allen Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Reyes, G. Articles by Duarte, J. Search for Related Content PubMed Articles by Reyes, G. Articles by Duarte, J. Related Collections Cardiac - physiology Coronary disease Minimally invasive surgery

How-to-do-it

Bone marrow laser revascularisation for treating refractory angina due to diffuse coronary heart disease

^a Department of Cardiovascular Surgery, Hospital Universitario La Princesa, Madrid, Spain
^b Department of Cardiothoracic Surgery, Mid America Heart Institute, St Luke's Hospital, Kansas City, MO, USA
^c Department of Haematology, Hospital Universitario La Princesa, Madrid, Spain

Received 29 August 2008; received in revised form 5 March 2009; accepted 12 March 2009.

^_* Corresponding author. Address: Hospital Universitario de La Princesa, c/Diego de León 62, 28006 Madrid, Spain. Tel.: +34 915202268; fax: +34 913202556. (Email: guillermo_reyes_copa{at}yahoo.es).

To increase the angiogenic response and clinical efficacy of TMR, the potential synergy and safety of combining TMR with concentrated autologous bone marrow derived stem cells was evaluated. Fourteen patients with diffuse coronary artery disease and medically refractory class III/IV angina who were not candidates for conventional therapies were treated using TMR in combination with intramyocardial injection of concentrated stem cells. At the time of surgery, autologous bone marrow (120 cc) was aspirated from the iliac crest and processed over 15 min into 20 cc of concentrated mononuclear cells using a centrifugal system (HARVEST, Boston, MA). A single device performed holmium: YAG:TMR (CardioGenesis, Irvine, CA) with injection of 1 cc of concentrated stem cells through three multi-holed needles into the border zone around each laser channel. There were no perioperative adverse events including no arrhythmias. Mean number of injected cells per milliliter were: total mononuclear cells (81.3 x 10⁶), CD34⁺ cells (0.6 x 10⁶), and CD133⁺ cells (0.37 x 10⁶). At 7 months mean follow-up average angina class was significantly improved (3.5 ± 0.5 vs 1.4 ± 0.5; p = 0.004). There was no death during the follow-up. Efficient delivery of stem cells combined with TMR in a single device seems to be safe and effective for treating unmanageable angina.

Key Words: Transmyocardial revascularisation • Stem cells • Angiogenesis • Laser